DIVERSIFIED HEALTHCARE TRUST (DHC): what the price requires

At today's price, DIVERSIFIED HEALTHCARE TRUST (DHC) is priced for today's economics sustained for ~5.5 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-19 · Source: https://boothcheck.com/report/DHC

Headline

FieldValue
TickerDHC
CompanyDIVERSIFIED HEALTHCARE TRUST
Current price$8.73/sh
CompositionSHOP 87% / Medical Office and Life Science Portfolio 13%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basisreit
Top-of-range FFO growth must hold for5.5y
Price-to-FFO14.9x
FFO yield6.7%

Solve inputs: computed at a 12.7% cost of equity; growth searched up to the 15% ceiling.

Reconcile: at the x-ray's 9.3% required return this reads ~3.4%/yr; the models below use their own rates.

How unusual the bet is: within-range

ReferenceValue
vs own history-0.25σ
cohort percentile (of 88 peers)69
sustained it ~5.5 years at this level55%
implied end-window share0%

Valuation X-Ray

The price is justified by relative-multiple; earnings-power/growth-DCF land below the price.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset1.30x3expensive
Earnings9.59x2expensive
Relative0.69x4justifies
Growth1.55x1expensive

Families that justify the price: Relative Families that call it expensive: Earnings, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 4.9%); the inversion above states its own rate.

Per-Model Detail (n=10)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$0.00—noNegative/zero FCF — equity value floored at $0
DCF Exit MultipleGrowth$0.00—noNegative/zero FCF or EBITDA — equity value floored at $0
Relative ValuationRelative$13.780.63xyesP/E 26.92x (blended: static sector reference 35x + trailing (TTM) 15x), scenarios: 22.9x / 26.9x / 31.0x (bear / base = reference held flat / bull), EV/EBITDA 20x
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$6.731.30xyesReference only (book value floor): BV/sh $6.73, ROE negative
Two-Stage Excess ReturnAsset$6.061.44xyesReference only (book value with convergence): BV/sh $6.73, ROE converges to ke
Discounted Future Market CapGrowth$5.651.55xyesRev $1.5B, growth 0% (input: historical growth; tapered), Terminal P/S: 1.2x / 1.4x / 1.6x (bear / base = today's held flat / bull, cap 8x)
Growth-Adjusted P/ERelative——no—
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings——no—
Residual IncomeAsset——no—
Graham NumberAsset$9.450.92xyes√(22.5 × FFO/share $0.59 × BVPS $6.73) — Graham's conservative floor
EV/EBITDA RelativeRelative$11.670.75xyesEBITDA $0.26B × sector EV/EBITDA 20.0x
FCF YieldEarnings——no—
SBC-Adj FCF YieldEarnings——no—
Ben Graham FormulaEarnings$0.4917.82xyesFFO/share $0.59 × (8.5 + 2×-5.0%) × (4.4 / 5.3%)
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative$37.830.23xyesRevenue $1.52B × sector P/S 6.0x
PEG Fair ValueRelative——no—
Earnings YieldEarnings$6.381.37xyesFFO/share $0.59 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelative$8.351.05xyesFFO/share $0.59 × 14.2x P/FFO (route cohort median, n=85); FFO $0.14B (FFO incl. D&A + impairments, FY2025, companyfacts), shares 241M
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Funds from operations (trailing)$141.7m
Share count CAGR (dilution)0.3%
Burning cashyes

REIT basis: leverage is read against funds from operations (FFO), not depreciation-gutted operating income. The header's implied growth runs on ADJUSTED FFO — FFO minus recurring maintenance capex — so the header's multiple and this leverage ratio use bases that differ by that capex; neither substitutes for the other. Net debt could not be resolved from the corporate debt tags in the filings (REIT notes and mortgage debt are often tagged outside the corporate ladder), so the leverage ratio is withheld rather than rendered from incomplete tags. Interest expense is not separately reported in the cached statements, so fixed-charge coverage cannot be computed.

Bullet Takeaways

Bull Case

Lead with the fear, because it is the right place to start: Diversified Healthcare Trust spent the last few years as a balance-sheet emergency, a senior-housing landlord crushed by the pandemic and weighed down by debt that looked, at one point, like it might not get refinanced. That bear case was real. The question is whether the data now undermines it, and increasingly it does. In 2025 the trust executed large asset sales that wiped out its 2025 and 2026 zero-coupon bond maturities and cut quarterly interest expense from $57.8 million to $37.0 million, and in April Moody's upgraded its corporate family rating to B3 from Caa1. A company moving up the ratings ladder while retiring its near-term maturities is a company stepping back from the edge.

The operating recovery underneath is the real engine. The senior-housing operating portfolio, the part that got hammered when COVID emptied buildings and inflated labor costs, is healing: same-property SHOP net operating income rose 13.5% year over year to $44.3 million, with NOI margins climbing to 14.9% on rate increases and a successful transition to new regional operators. Senior housing has powerful demographic tailwinds, the aging population is not a forecast but a certainty, and as occupancy rebounds toward pre-pandemic levels, the operating leverage is enormous, because the buildings are already built and largely fixed-cost. Management guides a 300 basis point occupancy gain for 2026, which would push SHOP NOI to $175 million to $185 million.

The valuation reflects a business the market still half-distrusts. Normalized funds from operations more than doubled year over year to $0.14 per share in the quarter, and full-year guidance of $0.52 to $0.58 per share implies the recovery continues. The medical-office and life-science portfolio provides a more stable, leased counterweight to the operating senior-housing exposure. The trust also owns real estate of genuine value behind the leverage, so the asset value provides a floor the equity sits above. The bull case is straightforward: a deleveraging healthcare REIT with a recovering senior-housing portfolio riding demographic tailwinds, where each quarter of occupancy gains both grows NOI and reduces the leverage ratio at once.

Bear Case

The bear case is about which assumptions the price has baked in, and the most fragile is that the senior-housing recovery proceeds smoothly and on schedule. At roughly 20 times adjusted funds from operations, the price assumes the trust grows that cash flow at the top of the REIT range for about six years. That is a demanding bet for a company still posting net losses, with a quarterly net loss of $43.3 million in the most recent period. The recovery is real, but it is early, and the price is paying for it to compound for years. Senior housing operating performance depends on occupancy, labor costs, and the execution of the new regional operators, any of which can disappoint, and the 10-K is candid that "our and our managers' and other operators' and tenants' businesses may not return to the levels experienced prior to the COVID-19 pandemic."

The leverage is what makes the recovery non-negotiable rather than merely desirable. Even after the asset sales, net debt sits near eight times EBITDA and fixed-charge coverage is thin at about 1.8 to 2.0 times, leaving little margin for error. The trust's own debt agreements constrain it: the filing notes that "covenants and conditions contained in our debt agreements may restrict our operations by increasing our interest expense and limiting our ability to make investments in our properties, sell properties securing our debt." A highly levered REIT in the middle of a recovery has to keep growing NOI just to maintain coverage, and if occupancy gains stall or interest costs rise on refinancing, the same leverage that amplifies the upside amplifies the downside. The asset sales that fixed the near-term maturities also shrank the portfolio, so the trust is recovering on a smaller base.

The governance structure is the structural concern many investors underweight. DHC is externally managed by RMR, and the filing acknowledges the conflict directly: senior officers "have duties to RMR, as well as to us, and we do not have their undivided attention," and "may have confl"icts of interest. External management aligns fees with assets under management, not necessarily with per-share value, and the RMR-managed entities have a long history of related-party transactions. For a company whose recovery depends on disciplined capital allocation, having a manager whose incentives are not perfectly aligned with shareholders is a real risk. The price already discounts a lot of pessimism, so the bear is not a simple overvaluation argument; the relative lens reads the stock as cheap. The bear is that the leverage, the early-stage recovery, and the external-management overhang combine to make the cash flow less reliable than the price assumes, and that a stumble in any one leaves a highly levered equity exposed.

Valuation

A healthcare REIT is valued on its adjusted funds from operations, not on depreciation-distorted earnings, and on that basis the price works out to roughly 20 times that cash flow. Inverted, the price assumes the trust grows adjusted funds from operations at the top of the REIT range for about six years. That is a recovery multiple, not a steady-state one: the price is paying for the senior-housing rebound to keep compounding, which the framework reads as within range given that the recent pace is consistent with what the trust has delivered, though it sits in the upper half of the REIT peer group's multiple.

The methods we use to triangulate split exactly along the recovery fault line. The relative lens reads the stock as cheap, landing above the price, while the earnings-power and growth lenses read it as expensive, because current cash earnings are still depressed by the senior-housing portfolio's incomplete recovery and the heavy interest load. The asset lens sits modestly above the price, anchored on the real estate, and for a REIT whose property is carried at depreciated cost, that asset value is the more reliable floor. The pattern says a turnaround priced on its recovery: the methods that look at today's depressed cash flow say expensive, and the methods that look at the asset base and peer multiples say there is value if the recovery lands.

Solvency is the binding constraint and must be read on REIT terms. Net debt sits near eight times EBITDA with fixed-charge coverage around two times, high leverage by any standard, though sharply improved from where it was before the 2025 asset sales and the Moody's upgrade. The trust is still generating GAAP losses as the senior-housing portfolio recovers, so the cash flow margin over its obligations is thin. The downside is bounded by the underlying real estate, healthcare property in medical office, life science, and senior housing, which has genuine value, but the equity sits behind a large debt load whose cost and refinancing terms matter enormously. The buyer at this price is making a leveraged bet on the senior-housing recovery continuing, where success deleverages and re-rates the equity and a stall leaves a thin coverage cushion exposed.

Catalysts

Diversified Healthcare Trust's first quarter of 2026 advanced the turnaround on two fronts at once. Revenue was $366.5 million, and while the trust still posted a net loss of $43.3 million, or $0.18 per share, normalized funds from operations more than doubled year over year to $33.1 million, or $0.14 per share. The operating driver was the senior-housing operating portfolio, where same-property NOI rose 13.5% to $44.3 million and margins expanded to 14.9%, powered by rate increases and the transition to new regional operators.

The balance-sheet progress was the other catalyst. Through asset sales executed in 2025, the trust eliminated its 2025 and 2026 zero-coupon bond maturities and cut quarterly interest expense from $57.8 million to $37.0 million, bringing net debt to annualized adjusted EBITDAre to 7.8 times and interest coverage to about 2.0 times. In April, Moody's upgraded the corporate family rating to B3 from Caa1, an external confirmation that the credit profile is improving. For a company that was recently a balance-sheet worry, removing near-term maturities and earning a ratings upgrade are exactly the de-risking events the equity needed.

Management raised the 2026 outlook, guiding total NOI of $297 million to $313 million and normalized funds from operations of $125 million to $140 million, or $0.52 to $0.58 per share, with SHOP NOI of $175 million to $185 million supported by an expected 300 basis point occupancy increase. That occupancy ramp is the single number that matters most from here. The catalysts to watch are the pace of senior-housing occupancy and NOI gains, continued progress on leverage reduction, and any further refinancing of the remaining debt. Continued recovery on those fronts is the deleveraging-and-re-rating story; a stall, against the leverage, is the bear's.

Peer Cohorts (Per Segment, With Filing Citations)

SHOP (reported)

Medical Office and Life Science Portfolio (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Q1 2026 results, May 2026 · Q1 2026 results · Q1 2026 guidance · Q1 2026 results and guidance

View the full interactive DHC report on boothcheck